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Abstract
Background: Epidemiological and animal studies have reported that prenatal nicotine exposure (PNE) leads to
obesity and type-2 diabetes in offspring. Central leptin-melanocortin signaling via hypothalamic arcuate
proopiomelanocortin (POMC) neurons is crucial for the regulation of energy and glucose balance. Furthermore,
hypothalamic POMC neurons were recently found to mediate the anorectic effects of nicotine through activation
of acetylcholine receptors. Here, we hypothesized that PNE impairs leptin-melanocortinergic regulation of energy
balance in first-generation offspring by altering expression of long non-coding RNAs (lncRNAs) putatively regulating
development and/or function of hypothalamic POMC neurons.
Methods: C57BL/6J females were exposed ad libitum to nicotine through drinking water and crossed with
C57BL/6J males. Nicotine exposure was sustained during pregnancy and discontinued at parturition. Offspring
development was monitored from birth into adulthood. From the age of 8 weeks, central leptin-melanocortin
signaling, diabetes, and obesity susceptibility were assessed in male offspring fed a low-fat or high-fat diet for
16 weeks. Nicotine-exposed and non-exposed C57BL/6J females were also crossed with C57BL/6J males expressing
the enhanced green fluorescent protein specifically in POMC neurons. Transgenic male offspring were subjected
to laser microdissections and RNA sequencing (RNA-seq) analysis of POMC neurons for determination of nicotine-
induced gene expression changes and regulatory lncRNA/protein-coding gene interactions.
Results: Contrary to expectation based on previous studies, PNE did not impair but rather enhanced leptin-
melanocortinergic regulation of energy and glucose balance via POMC neurons in offspring. RNA-seq of laser
microdissected POMC neurons revealed only one consistent change, upregulation of Gm15851, a lncRNA of yet
unidentified function, in nicotine-exposed offspring. RNA-seq further suggested 82 cis-regulatory lncRNA/protein-
coding gene interactions, 19 of which involved coding genes regulating neural development and/or function, and
revealed expression of several previously unidentified metabolic, neuroendocrine, and neurodevelopment pathways
in POMC neurons.
Conclusions: PNE does not result in obesity and type 2 diabetes but instead enhances leptin-melanocortinergic
feeding and body weight regulation via POMC neurons in adult offspring. PNE leads to selective upregulation of
Gm15851, a lncRNA, in adult offspring POMC neurons. POMC neurons express several lncRNAs and pathways
possibly regulating POMC neuronal development and/or function.
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Background
The adipocyte-secreted hormone leptin has critical anor-
ectic and body weight-lowering actions that are medi-
ated by the central melanocortin system [1, 2]. The
melanocortin system consists of first order signaling
neurons in the hypothalamic arcuate nucleus comprising
neuropeptide Y (NPY) and Agouti-related protein
(AgRP) co-expressing neurons and of proopiomelano-
cortin (POMC)-expressing neurons. These first order
signaling neurons project to second order signaling neu-
rons expressing melanocortin 3 and 4 receptors (MC3/
4-Rs) located in several hypothalamic and extrahypotha-
lamic areas, where they exert anorectic actions, includ-
ing the periventricular nucleus (PVN), a satiety center,
and the lateral hypothalamic area (LHA), a feeding cen-
ter. POMC is a precursor polypeptide for α-melanocyte-
stimulating hormone (α-MSH). α-MSH acts as an
agonist to MC3/4-Rs of second order signaling neurons
in the PVN to inhibit food intake and increase energy
expenditure. AgRP is an antagonist of α-MSH at MC3/4-
Rs and potent activator of food intake and body weight
gain. Leptin regulates transcription of the genes encoding
POMC and AgRP. Leptin binds to leptin receptors
expressed in POMC and NPY/AgRP neurons. This trig-
gers phosphorylation and activation of Janus kinase 2
(JAK2), which in turn phosphorylates signal transducer
and activator of transcription 3 (P-STAT3). P-STAT3
homodimerizes and translocates to the nucleus to promote
transcription of the POMC gene and inhibit transcription
of the AgRP gene [3]. Leptin also stimulates release of α-
MSH from POMC neurons [4] and inhibits release of
AgRP from NPY/AgRP neurons [5]. Independently of de-
creasing food consumption and body weight, leptin signal-
ing via hypothalamic POMC neurons potently decreases
glycemia and increases locomotor activity, thereby pre-
venting hyperglycemia and normalizing physical activity of
morbidly obese, severely diabetic, and hypoactive, leptin-
receptor deficient Lepr db/db mice [6].
Mutations of the leptin, leptin receptor, POMC, and
MC4-R genes lead to severe obesity in rodents and in
humans, underscoring the importance of central leptin-
melanocortin signaling for the regulation of energy bal-
ance [7–9]. Furthermore, common human obesity is fre-
quently associated with leptin resistance characterized
by an inability of leptin to decrease body weight.
Nicotine has anorectic effects. One underlying mech-
anism is the activation of hypothalamic POMC neurons
by nicotinic α3β4 acetylcholine receptors and the subse-
quent activation of MC4-R expressing target neurons in
the PVN [10]. The metabolic consequences of gesta-
tional nicotine exposure in first-generation offspring
have been investigated in human epidemiological studies
[11–14] and rodent models [15–18]. These studies con-
cluded that gestational nicotine exposure increases the
risk for obesity and type 2 diabetes in offspring. Further-
more, it was reported that in utero or early postnatal
nicotine exposure upregulates POMC mRNA in neonate
rhesus macaque [19, 20]. These observations led us to
hypothesize that gestational nicotine exposure impacts
leptin-melanocortinergic regulation of energy balance in
first-generation offspring.
More than 70 % of the mammalian genome is tran-
scribed as non-coding RNAs (ncRNAs) of various sizes
ranging from 20 nucleotides to over 100 kb [21, 22].
NcRNAs are subdivided into short and long ncRNAs
(lncRNAs), which are shorter and longer than 200 nucle-
otides, respectively [23], as well as processed transcripts,
which do not contain an open reading frame, do not
contain retained introns, and cannot be placed in the
short and long ncRNA group. Similar to protein-coding
mRNAs, lncRNAs can be spliced, polyadenylated, and
capped [23]. LncRNAs are subdivided into: (1) antisense
RNAs, which are transcribed from the opposite DNA
strand of a protein-coding gene overlapping its intronic
and exonic sequences; (2) long intergenic non-coding
RNAs (lincRNA) transcribed from intergenic DNA re-
gions; (3) sense-intronic RNAs transcribed from introns
of a protein-coding gene on the same DNA strand with
no overlap of exonic sequence; (4) sense-overlapping
RNAs containing a protein-coding gene in one of its
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introns on the same DNA strand with no overlap of ex-
onic sequence; and (5) 3′-overlapping ncRNAs, which
are transcribed from the 3′-untranslated region of a lar-
ger gene. LncRNAs are predominantly localized in the
nucleus at usually much lower expression levels than
mRNAs.
While lncRNAs were initially believed to represent
transcriptional noise, studies in recent years have re-
vealed developmental-, tissue- and cell-type-specific ex-
pression of lncRNAs [24, 25] and regulatory roles in
important biological processes such as X-chromosome
inactivation in females, silencing of tumor suppressor
genes, mediation of DNA damage and cellular stress re-
sponses, gene imprinting, heterochromatin spreading
across DNA insulator sequences, regulation of stem cell
pluripotency, cell fate specification, and neural develop-
ment [26–30]. However, although many different bio-
logical functions have been assigned to lncRNAs, most
lncRNAs lack functional annotations. LncRNA genes
show poorer sequence conservation than protein-coding
genes although well-conserved lncRNAs with biologic-
ally important functions exist [31]. The number of
lncRNA genes has dramatically increased in late evolu-
tion and appears to scale with genome size. Meanwhile,
the number of protein-coding genes has not markedly
increased during late evolution. Therefore, one emergent
hypothesis is that the increase in lncRNA genes contrib-
utes to regulatory and organismal complexity [32].
LncRNAs can regulate expression of flanking or overlap-
ping coding genes (“cis-regulation”) or far distant coding
genes located on the same or another chromosome
(“trans-regulation”) in a positive (concordant) or nega-
tive (discordant) manner [25, 33, 34]. LncRNA-guided
gene regulation involves epigenetic, transcriptional, and
post-transcriptional mechanisms. LncRNAs are thought
to provide scaffolds for histone methyltransferases, his-
tone acetylases, and DNA methyltransferases [26, 27],
and can regulate splicing, editing, or degradation of
protein-coding RNAs [26].
Here we interrogated whether PNE alters expression
of lncRNAs with putative roles in hypothalamic
POMC neuronal development/function and leptin-
melanocortinergic regulation of energy balance in
first-generation offspring in a mouse model of human
maternal nicotine exposure from adolescence until
parturition. We found that PNE does not impair but
rather enhances leptin-melanocortinergic regulation of
energy balance in first-generation offspring and select-
ively upregulates expression of Gm15851, a lncRNA
of yet unidentified function, in hypothalamic POMC
neurons. Furthermore, we report expression of several
signaling pathways and lncRNAs that might regulate




Animals used in the study were from the C57BL/6J
mouse strain (RRID:IMSR_JAX:000664, Jackson Labora-
tories, Bar Harbor, ME, USA) or transgenic mice ex-
pressing the enhanced green fluorescent protein (EGFP)
in hypothalamic POMC neurons (C57BL/6J-Tg(Pomc-
EGFP)1Low/J, RRID:IMSR_JAX:009593, Jackson Labora-
tories, Bar Harbor, ME, USA). Metabolic, hormonal,
hypothalamic gene expression and leptin-signaling stud-
ies were conducted in C57BL/6J male offspring. RNA se-
quencing (RNA-seq) studies of laser microdissected
POMC neurons were conducted in POMC-EGFP trans-
genic male offspring. POMC-EGFP transgenic offspring
were tail biopsied at postnatal day 17 and genotyped
using established PCR protocols provided by the Jackson
Laboratories. Offspring were weaned at postnatal day 21
and kept in groups of 3–4 mice per cage. Male offspring
were singly housed with environmental enrichment from
the age of 8 weeks onwards until the end of the study.
All mice were housed in a pathogen-free barrier animal
facility and kept in a temperature-controlled (22 ±
0.5 °C) and humidity-controlled (50 %) animal room
on a 12 h light/dark schedule with light on at 07:00
and free access to food and water.
Prenatal nicotine exposure
Six-week-old females were treated for 4 weeks ad libi-
tum with drinking water containing 200 μg/mL nicotine
hydrogen tartrate sweetened with 2 % saccharin (w/v),
pH 7.4 [35]. Controls were administered pH-matched
drinking water containing the equivalent amount of tar-
taric acid and 2 % saccharin (w/v). The inclusion of sac-
charin was required because nicotine in the drinking
water causes taste-aversion [36, 37] and reduces mater-
nal fluid intake [35]. Drinking solutions were changed
twice a week. At the age of 10 weeks, females were
mated to unexposed males. Nicotine administration con-
tinued throughout mating and pregnancy and was dis-
continued at parturition. Mothers were allowed only one
pregnancy.
Determination of plasma cotinine
Plasma cotinine levels were determined using a Cotinine
(Mouse/Rat) enzyme linked immunosorbent assay kit
(Abnova, Walnut, CA, USA) following the manufac-
turer’s directions. All samples were assayed in duplicates.
The intra-assay coefficient of variation (CV) of the co-
tinine ELISA measurements was 3.9 %.
Diets
All animals were fed a standard (low-fat) diet (STD) with
a metabolizable energy density of 3.1 kcal/g derived from
28.7 % kcal protein, 58.53 % kcal carbohydrates, and
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12.73 % kcal fat (5010, LabDiet, St Louis, MO, USA). A
subset of male offspring was subjected to a high-fat diet
(HFD) with a metabolizable energy density of 4.7 kcal/g
derived from 17 % kcal protein, 43 % kcal carbohydrates,
and 41 % kcal fat, containing 0.21 % (w/w) Cholesterol
(Western Diet, Research Diets, Inc., New Brunswick, NJ,
USA) starting from the age of 8 weeks.
Determination of energy balance
Body composition (body fat content, lean mass, and
body fluid) was determined by nuclear magnetic reson-
ance (minispec TD-NMR Analyzer, Bruker Optics, Inc.,
Billerica, MA, USA). Food consumption of singly housed
animals was measured twice a week. Fresh food pellets
were provided twice a week to avoid temperature-
dependent spoilage. Any residual bits of food in the
bedding were included in the measurements. A compre-
hensive laboratory animal monitoring system (Columbus
Instruments, Columbus, OH, USA) determined oxygen
consumption, carbon dioxide production, heat produc-
tion, locomotor activity, and food intake simultaneously
in individual animals. Measurements were taken in
metabolic cages placed in a temperature-controlled en-
closure set at 23.5 °C. Mice were acclimated to the meta-
bolic cages for 72 h prior to measurements for an
additional 72 h.
Determination of glucose balance
Blood glucose measurements were carried out with a
OneTouch glucometer (LifeScan, Inc.). Blood glucose
and insulin concentrations were determined by tail
venipuncture and submandibular bleeding, respectively,
between 09:00 and 10:00 following 14 h of fasting. Insu-
lin was measured by enzyme linked immunosorbent
assay (Ultra Sensitive Mouse Insulin ELISA Kit, Crystal
Chem, Inc., Chicago, IL, USA). All samples were assayed
in duplicates. The intra-assay CV of the insulin ELISA
measurements was 9.9 %. Glucose tolerance tests (GTTs)
were conducted in 14 h fasted mice by injecting i.p. glu-
cose 1 g/kg body weight. Insulin tolerance tests (ITTs)
were conducted in 6 h fasted mice by injecting i.p.
Insulin (Humulin R, Eli Lilly, Indianapolis, IN, USA)
0.5 IU/kg body weight. Blood glucose concentrations
for the GTT and ITT were measured from the tail
tip. Calculating the area under the curve (AUC) of
glucose concentration-time point graphs using Prism
5 (RRID:SCR_002798, GraphPad Software, La Jolla,
CA, USA) quantitatively assessed glucose and insulin
tolerance.
Determination of plasma lipids
All plasma lipids were determined using VITROS®
Chemistry Products and analyzer (Ortho-Clinical Diag-
nostics, Inc., Rochester, NY, USA). Total cholesterol
(Tot Chol) was measured by the VITROS CHOL Slide
method. High-density lipoprotein cholesterol (HDL-C)
was determined by the VITROS direct HDL-C (dHDL)
slide assay. Triglycerides were measured by the VITROS
TRIG Slide method. Low density lipoprotein choles-
terol (LDL-C) and Very low density lipoprotein chol-
esterol (VLDL-C) concentrations were calculated as
follows: VLDL-C = TG/5; LDL-C = Tot Chol – HDL-
C – VLDL-C.
Refeeding experiments and determination of Leptin and
MTII sensitivity
Refeeding experiments were conducted as described pre-
viously [38]. Mice were fasted overnight for 12 h and
then injected i.p. leptin 5 mg/kg (A.F. Parlow National
Hormone and Peptide Program, Torrance, CA, USA),
Melanotan II (MTII) 5 mg/kg (Tocris, Ellisville, MO,
USA), or the equivalent volume of vehicle (phosphate
buffered saline (PBS)). Body weight was determined
prior to injection, as well as 1 h, 2 h, 4 h, 8 h, and 24 h
post injection. A known amount of food was added to
each cage immediately after injection and food intake
was measured 1 h, 2 h, 4 h, 8 h, and 24 h post injection.
Mice had unlimited access to water during the entire ex-
periment. Plasma leptin concentrations were determined
by ELISA (Mouse Leptin ELISA Kit, Crystal Chem, Inc.,
Chicago, IL, USA). All samples were assayed in dupli-
cates. The intra-assay CV for the leptin ELISA measure-
ments was 5.1 %.
Immunofluorescence detection and quantification of
leptin-induced nuclear STAT3 phosphorylation
Mice were fasted overnight for 14 h and injected i.p. lep-
tin 5 mg/kg (n = 3) or the equivalent volume of vehicle
(PBS) (n = 2–3). Thirty minutes post injection, animals
were perfused with 10 % formalin under general
anesthesia. Brains were post-fixed in 10 % formalin for
24 h at 4 °C and paraffine-embedded. Coronal sections
were cut at 6 μm, deparaffinized, and rehydrated
through sequential washes in Xylene, 95 % ethanol, 70 %
ethanol, and water. Sections were permeabilized with
PBS/0.3 % Triton X-100 for 10 min and blocked with
5 % normal goat serum in PBS/0.3 % Triton X-100 for
1 h at room temperature. Sections were incubated over-
night at 4 °C with mouse monoclonal Phospho-STAT3
(Tyr 705) antibody (Cell Signaling Technology, Danvers,
MA, USA; Cat# 4113S, RRID: AB_2198588) diluted 1:50
and rabbit anti-POMC antibody (Phoenix Pharmaceuti-
cals, Inc., Burlingame, CA, USA; Cat# H-029-30, RRID:
AB_2307442) diluted 1:300 in 2 % goat serum/PBS/0.3 %
Triton X-100. Another set of sections was incubated
with rabbit monoclonal Phospho-STAT3 (Tyr 705)
(D3A7) antibody (Cell Signaling Technology, Danvers,
MA, USA; Cat# 9145S, RRID:AB_561305) diluted 1:100
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in 1 % BSA/PBS/0.3 % Triton X-100. Sections were
washed with PBS and then incubated with anti-rabbit
IgG and anti-mouse IgG antibodies conjugated with the
Alexa fluorochromes 488 and 555, respectively. After
rinsing sections with PBS, Prolong® Gold Antifade Re-
agent (LifeTechnologies, Grand Island, NY, USA) was
added and coverslips were mounted. Sections were ana-
lyzed on an inverted Leica Microsystems SP5 imaging
system with an XYZ automated stage and AOBS wave-
length controls for laser tuning. The system was
equipped with a set of lasers providing the following
laser lines: 405, 458, 476,488, 496, 514, 561, and 633 nm.
The system ran under the Leica Application Suite (LAS)
AF 2.7.1 software. Images were acquired using a 20× dry
lens with a numerical aperture of 0.7. Images were
acquired from 3–4 matched (rostral-caudal) hypothalamic
sections encompassing the bregma coordinates −1.34 mm
and −2.06 mm [39]. P-STAT3 reactive POMC neurons
were identified by co-localization of nuclear P-STAT3 and
cytosolic POMC-polypeptide [38]. Differences in leptin-
induced P-STAT3 signaling were assessed by comparing
average counts of P-STAT3-positive ARC neurons or P-
STAT3-positive POMC neurons in brain sections of indi-
vidual mice (n = 3 mice per group).
Determination of hypothalamic POMC mRNA expression
Total RNA was isolated from microdissected whole
hypothalami using the RNeasy Mini kit (Qiagen). Total
RNA (500 ng) was reverse transcribed (Superscript III
first strand cDNA synthesis kit; Invitrogen, Thermo-
Fisher Scientific). Real-time PCR reactions were carried
out on an ABI 7900HT light cycler using the Taqman
Universal Master Mix and validated gene-specific Taq-
man expression assays for proopiomelanocortin and β-
actin (Applied Biosystems, ThermoFisher Scientific).
POMC mRNA was normalized to β-actin mRNA by the
ΔΔCt method.
Laser micro-dissections and RNA extractions of hypothalamic
POMC neurons
Prenatally nicotine-exposed and non-exposed transgenic
adult male mice expressing the enhanced green fluores-
cent protein in hypothalamic POMC neurons [40] were
euthanized in week 10 of the STD by CO2 inhalation
followed by cervical dislocation and decapitation. Brains
were quickly removed, fresh-frozen in dry ice, and stored
at −80 °C. Brains were sectioned on a cryostat Leica CM
3050 S at 15 μm. Sections were attached onto Director®
slides (Expression Pathology, Inc., Rockville, MD, USA),
dehydrated in acetone for 1 min at room temperature,
and desiccated for 2 min in a closed petri-dish contain-
ing dessicant (Drierite). Slides were immediately placed
upside-down on the stage of a laser microdissection
microscope Leica AS LMD equipped with a HCX PL
Fluotar 20×/0.4 NA lens and a Hitachi HV-C20A cam-
era. POMC-GFP neurons in the mediobasal hypothal-
amus were visualized by the green fluorescent
appearance of their cell bodies, which were collected dir-
ectly in 20 μL lysis buffer of the RNAequous microex-
traction kit (Life Technologies, ThermoFisher Scientific).
Collections from individual sections were not allowed to
continue for more than 30 min. Lysates were immedi-
ately frozen on dry ice and stored at −80 °C. Between
400 and 600 POMC neurons were isolated from the en-
tire hypothalamus of each mouse brain. RNA was iso-
lated following the directions provided in the
RNAequous microextraction kit. RNA samples were run
on an electropherogram (2100 Bioanalyzer, Agilent
Technologies) for determination of RNA quality, con-
centration, and yield. Samples with RNA integrity num-
bers (RIN) above 6 were used for generation of RNA-seq
libraries.
RNA sequencing
A range of 1–2 offspring coming from five different
nicotine-exposed dams (n = 6 PNE offspring total) and
1–2 offspring coming from four different non-exposed
dams (n = 5 control offspring total) were subjected to
RNA-seq. Directional RNA-seq libraries were generated
from a range of 200–400 pg total RNA using the Ovation
Single Cell RNA-seq kit (NuGen, San Carlos, CA, USA)
following the manufacturer’s directions. All RNA-seq li-
braries were run on an electropherogram (2100 Bioanalyzer,
Agilent Technologies) to confirm the expected frag-
ment size distribution. Libraries were paired-end
sequenced on Illumina’s HiSeq2000 sequencer. Of all
read-pairs, 90–95 % passed Illumina’s quality filters.
For subsequent alignments, the first eight nucleotides
of the forward read were trimmed according to the
manufacturer’s directions for analysis of Ovation
Single Cell RNA-seq libraries. Pass-filter read-pairs were
aligned to the mouse reference mm10 genome using STAR
[41]. Read-pairs aligning to the genome with more than
two mismatches or aligning to more than one site of the
genome were discarded from further analyses. The aligned
read-pairs were run through HTSeq (RRID:SCR_005514)
for transcript quantification against the GENCODE
reference gtf file vM4 for the mouse mm10 genome [42].
After all features had been quantified the data was run
through three differential expression calculators in edgeR
(RRID:SCR_012802) [43], DESeq (RRID:SCR_000154)
[44], and baySeq (RRID:SCR_012795) [45]. The intersec-
tion of the three methods was taken and transformed into
a list of the final differentially expressed features. Differen-
tially expressed features were determined by cutoff ad-
justed p values of 0.05 across all three methods. For
heatmap generation, the default parameters of the heat-
map.2 function within the R package gplots v2.16.0
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(https://cran.r-project.org/web/packages/gplots/index.
html) were used. Function and expression annotations for
coding and non-coding genes were retrieved from the
Protein ANalysis THrough Evolutionary Relationships
(PANTHER) Classification System (RRID:SCR_004869)
[46]. Expression differences of Gm15851 were confirmed
by strand-specific qRT-PCR in the same RNA samples
used for RNA-seq (n = 6 PNE offspring; n = 5 control
offspring). Following quantitation of RNA concentra-
tions by the RNA 6000 pico assay on an Agilent 2100
Bioanalyzer (Agilent Technologies), 500 pg of total RNA
was reverse transcribed using a strand-specific primer
(sequence: TCCTGGATCTGCAGCACAATCG) anneal-
ing to the Gm15851 transcript and the superscript IV first
strand synthesis system (ThermoFisher Scientific). Reac-
tion conditions followed the manufacturer’s directions.
After cDNA synthesis, the RNA template was digested
with RNAse H. Real-time PCR reactions were run in trip-
licate using a custom-built Taqman gene expression assay
for Gm15851 (forward primer sequence: CCGGCACGTT
GCTGATC; reverse primer sequence: CTCCTTCAAC
ATCTCCAACTTGCT; Taqman reporter sequence:
CCACCTGTCTCACAACAA) (ThermoFisher Scientific)
on a QuantStudio 7 Flex real time PCR system (Thermo-
Fisher Scientific). Ct values were determined with Quant-
Studio software (ThermoFisher Scientific). Dilutions of an
expression plasmid containing the cDNA sequence of
Gm15851 were assayed in parallel to generate a reference
standard curve and quantitate the relative amounts of
Gm15851 in each sample.
Data analysis
Study groups consisted of n = 7–9 male offspring unless
otherwise indicated. Male offspring were selected from
n = 6 nicotine-exposed and n = 7 non-exposed litters.
Male offspring in each study group originated from n =
3–4 different dams. Statistical analyses were conducted
with GraphPad Prism 5 (RRID:SCR_002798, GraphPad
Software, La Jolla, CA, USA). Data were subjected to
various normality tests (Kolmogorov–Smirnov, D’Agos-
tino–Pearson Omnibus, and Shapiro–Wilk) prior to per-
forming the following parametric or non-parametric
statistical tests: two-tailed unpaired t test, Welch’s test
for uneven variances, and Mann–Whitney test for two-
group comparisons; Fisher’s exact test for contingency
analyses of postnatal survival; two-way ANOVA for de-
termination of the effect of PNE and diet on metabolic,
hormonal, and gene expression parameters, and the
combined effect of PNE and leptin/MTII on body weight
gain and food intake in refeeding experiments; two-way
repeated measures (RM) ANOVA for determination of
the effect of nicotine on maternal fluid intake, food in-
take, and body weight before and during gestation and
the effect of PNE on glucose and insulin tolerance;
Bonferroni post-tests following ANOVA for two-group
comparisons. The α-value was set at 0.05 for each statis-
tical test. Data were expressed as mean ± SEM.
Results
Prenatal nicotine exposure and early postnatal
development of offspring used in the study
C57BL/6J females were exposed to nicotine ad libitum
through drinking water containing nicotine hydrogen
tartrate salt at a concentration of 200 μg/mL. Controls
received drinking water containing the equivalent
amount of pH-matched tartaric acid. Nicotine exposure
started at the age of 6 weeks, continued throughout mat-
ing at the age of 10 weeks and gestation, and ended at
parturition. Since nicotine causes taste aversion [36, 37],
the drinking water of both, nicotine-exposed and non-
exposed dams was sweetened with 2 % (w/v) saccharin
[35]. Nicotine moderately reduced weekly fluid volume in-
take before and during gestation (Pre-Gestation: F1,12 =
5.41, p = 0.06; Gestation: F1,36 = 23.4, p = 0.0001; RM
ANOVA) (Fig. 1a). The mean daily water intake of
nicotine-exposed females (≈2 mL/10 g body weight/24 h
at 6–8 weeks of age) remained moderately above the mean
values reported for wild-type mice of unspecified sex,
strain, and age (1.5 mL/10 g body weight/24 h) and those
reported for C57BL/6 females aged 7–9 weeks (1.64 mL/
10 g body weight/24 h, Mouse Phenome Data Base, The
Jackson Laboratory). Mean daily nicotine ingestion calcu-
lated based on fluid intake was 0.77 ± 0.03 mg/day (n = 4)
before pregnancy and 0.92 ± 0.03 mg/day (n = 10) during
pregnancy (Fig. 1b). Moreover, the plasma levels of cotin-
ine, a metabolite of nicotine, and indicator of tobacco
smoke exposure in humans [47] determined after 4 weeks
of ad libitum nicotine intake were in the range of 137.4–
385.1 ng/mL (mean value: 245 ± 0.03 ng/mL; n = 6)
(Fig. 1c). These plasma cotinine values are within the
range reported in humans who smoke 15–24 cigarettes/
day and > 25 cigarettes/day and exhibit serum cotinine
concentrations of 230–280 ng/mL and 260–300 ng/mL,
respectively [48]. Plasma cotinine was undetectable in
age-matched non-exposed dams. Ad libitum nicotine in-
gestion had no significant impact on maternal food intake
(F1,12 = 3.04, p = 0.13; RM ANOVA) (Fig. 1d) or maternal
body weight (F1,44 = 3.4, p = 0.08; RM ANOVA) (Fig. 1e)
as reported for the C57BL/6 mouse strain [35]. Dams were
allowed only one pregnancy. Nicotine-exposed and non-
exposed litters displayed no significant difference in mean
litter size at postnatal day (PD)1 (PNE: 6.7 ± 0.37; control:
6.1 ± 0.3; n = 10 litters/group; t18 = 1.24, p = 0.23; t test).
Postnatal survival of PNE offspring tended to be more
compromised than that of control offspring (62.7 % versus
73.8 %) by PD21 but contingency analysis of alive and
dead PD21 offspring revealed no significant differences
between groups (p = 0.19 by two-sided Fisher’s exact test)
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and litter sizes were the same in both groups by PD21
(PNE: 4.2 ± 1.02; control: 4.5 ± 0.8; n = 10 litters/group; t18
= 0.22, p = 0.82; t test). However, PNE led to moderate de-
creases in mean body weight (PNE: 6.55 ± 0.23 g; control:
7.16 ± 0.14 g; n = 42–45/group; p = 0.027; Mann–Whitney
test) and mean crown-rump length (PNE: 5.77 ± 0.12 cm;
control: 6.15 ± 0.45 cm; n = 42–45/group; p = 0.037;
Mann–Whitney test) of PD21 offspring. Therefore, to ex-
clude differences in maternal care as a confounding factor
in the assessment of the long-term metabolic conse-
quences of PNE, we selected for the metabolic studies six
nicotine-exposed litters and seven non-exposed litters
showing similar postnatal survival rates (PNE: 85.7 %; con-
trol: 88.4 %), and without differences at PD21 in mean litter
size (PNE: 5.7 ± 0.7; control: 5.4 ± 0.5; t11 = 0.28, p = 0.78; t
test), mean body weight (PNE: 7.19 ± 0.12 g; control: 7.15 ±
0.15 g; n = 34–38/group; p = 0.47; Mann–Whitney test),
and mean crown-rump length (PNE: 6.12 ± 0.06 cm; con-
trol: 6.16 ± 0.08 cm; n = 34-38/group; p = 0.41; Mann–
Whitney test).
Prenatal nicotine exposure does not cause obesity or
type 2 diabetes in adult first-generation offspring
Male offspring were subjected to a 16-week STD or
HFD. PNE moderately decreased cumulative food intake
of STD mice (PNE: 1268 ± 9.5 kcal, n = 7; control: 1363
± 37.6 kcal, n = 8) and HFD mice (PNE: 1416 ± 13.48 kcal,
n = 8; control: 1450 ± 27.6 kcal, n = 8) (Fig. 2a). Body
weight measurements revealed no differences between
PNE and control offspring fed the same diet (Fig. 2b).
Moreover, PNE had no impact on body composition as
determined by NMR measurements of relative fat, lean,
and fluid mass (Fig. 2c–e). Plasma lipid levels were pro-
filed in week 16 of the diets and were the same in
nicotine-exposed and non-exposed offspring (Table 1).
To more accurately characterize PNE-induced changes
in energy balance, we subjected individual male offspring
in week 10 of the STD and HFD to simultaneous deter-
minations of food intake, locomotor activity, and energy
expenditure by indirect calorimetry in metabolic cages.
PNE moderately reduced 24-h caloric intake of STD
mice (PNE: 12.11 ± 0.38 kcal/24 h, n = 7; control: 13.94
± 0.52 kcal/24 h, n = 7; t12 = 2.85 and p = 0.015 by t test)
and HFD mice (PNE: 14.21 ± 0.34 kcal/24 h, n = 8; con-
trol: 17.16 ± 1.16 kcal/24 h, n = 7; F1,25 = 12.9 and p =
0.0014 by two-way ANOVA; p < 0.01 by Bonferroni post-
test) (Fig. 2f ). PNE had no impact on 24-h energy ex-
penditure, 24-h oxygen consumption, 24-h carbon diox-
ide production, or the respiratory exchange rate of
offspring on the STD or HFD (Fig. 2g–j). However, we
noted a moderate enhancement in 24-h vertical activity
of PNE offspring relative to control offspring under HFD
conditions, possibly reflecting increased rearing (Fig. 2k–l).
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Pre-gestation Gestation 
Fig. 1 Ad libitum nicotine intake led to high plasma cotinine levels, moderately reduced fluid intake, and did not alter body weight or food
consumption of dams. a Twenty-four-hour fluid intake was determined in group-housed females (n = 4 cages of 3 females/group) before pregnancy
and in individually housed females (n = 10/group) during gestation. b Nicotine intake before (n = 4) and during pregnancy (n = 10) was calculated
based on 24-h fluid intake. c Plasma cotinine levels were determined by enzyme-linked immunosorbent assay (ELISA) after 4 weeks of nicotine
ingestion. Plasma cotinine was detected in all nicotine-exposed females (n= 6) and was undetectable in non-exposed females (n= 6). d Twenty-four-
hour food intake was determined in group-housed females (n= 4 cages of 3 females/group) before pregnancy. e Body weight was determined weekly
before pregnancy (n = 12/group). Data were analyzed by two-way RM ANOVA followed by Bonferroni post-test (a) or by Mann–Whitney
test (c) (**, p < 0.01). All data are expressed as mean ± SEM
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Fig. 2 (See legend on next page.)
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control animals relative to STD feeding (Fig. 2k–l) as we
have reported earlier [6, 49].
PNE offspring displayed a transient decrease in fasting
glycemia in week 8 of the STD (PNE: 80.3 ± 1.6 mg/dl,
n = 7; control: 106.3 ± 5.3 mg/dl, n = 9; p < 0.001 by
Bonferroni post-test) (Fig. 2m). Subsequent fasting glu-
cose measurements in weeks 12 and 16 of the STD and
in weeks 8, 12, and 16 of the HFD revealed no differ-
ences in fasting glycemia (Fig. 2m). A GTT conducted in
week 8 of the diets revealed increased glucose tolerance
in PNE offspring relative to control offspring under STD
conditions (area under the curve (AUC): PNE, 19,348 ±
751 mg/dl, n = 7; controls, 23,069 ± 593 mg/dl, n = 8;
p < 0.05 by Bonferroni post-test) but not under HFD con-
ditions (Fig. 2o, q). An ITT conducted in week 10 of the
diets showed no difference in insulin sensitivity between
PNE and control groups (Fig. 2p, r). Fasting plasma insulin
concentrations determined in week 16 of the diets were
similar in PNE and control offspring (Fig. 2n). We con-
clude that PNE did not render offspring more susceptible
to obesity or diabetes development but instead moderately
decreased food intake and fasting glycemia.
Prenatal nicotine exposure enhances leptin-melanocortin
signaling in adult first-generation offspring
We measured the anorectic and body weight lowering ac-
tions of leptin and the MC3/4-R agonist MTII in pre-
natally nicotine-exposed and non-exposed adult first-
generation offspring. Mice were fasted overnight, injected
i.p. leptin, MTII, or vehicle (PBS), and immediately
offered food, followed by determination of body weight
and cumulative food consumption at defined time
points [38].
Leptin administration examined the response of first
order signaling neurons controlling food intake and
body weight, including hypothalamic POMC neurons.
Vehicle-injected and leptin-injected PNE offspring
tended to gain less body weight than vehicle-injected
and leptin-injected control offspring both under STD
conditions (t = 1 h: F1,27 = 4.71, p = 0.04; t = 2 h: F1,27 =
14.5, p = 0.0007; t = 8 h: F1,27 = 9.6, p = 0.005; t = 24 h:
F1,27 = 9.9, p = 0.004; two-way ANOVA) (Fig. 3a) and
HFD conditions (t = 1 h: F1,28 = 7.9, p = 0.009; t = 2 h:
F1,28 = 3.3, p = 0.08; two-way ANOVA) (Fig. 3b). PNE off-
spring also tended to be more sensitive to leptin-
mediated inhibition of body weight gain under STD con-
ditions (t = 2 h: t14 = 1.89, p = 0.048; t test) (Fig. 3a) and
HFD conditions (t = 1 h: t14 = 1.89, p = 0.079; t = 2 h: t14 =
2.21, p = 0.045; t test) (Fig. 3b). Moreover, vehicle-injected
PNE offspring gained less body weight than vehicle-
injected control offspring both on the STD (t = 2 h: p <
0.05; t = 8 h: p < 0.01; Bonferroni post-test) (Fig. 3a) and
HFD (t = 1 h: t14 = 2.08, p = 0.057; t test) (Fig. 3b). PNE did
not impact food intake of vehicle-treated and leptin-
treated offspring on the STD (Fig. 3c) but moderately
lowered food consumption of vehicle-treated and leptin-
treated offspring on the HFD (t = 1 h: F1,28 = 4.6, p = 0.04;
two-way ANOVA). Furthermore, PNE modestly increased
(See figure on previous page.)
Fig. 2 First-generation adult PNE offspring do not develop adiposity or type 2 diabetes. a Cumulative food intake of PNE offspring and control
offspring (in kcal) was determined after 16 weeks of diet. b Monthly body weight measurements concomitant with body composition measurements.
c–e Relative body fat (c), relative lean mass (d), and relative fluid mass (e) in % of body weight (BW) determined monthly by nuclear magnetic resonance.
f–l metabolic cage measurements of 24-h food intake (FI) (f), 24-h energy expenditure (EE) (g), 24-h oxygen consumption rates (VO2)
(h), 24-h carbon dioxide production rates (VCO2) (i), respiratory exchange ratio (RER) (j), and 24-h locomotor activity (k, l) in week 10 of
the diets. EE, VO2, and VCO2 were normalized to the lean mass determined by nuclear magnetic resonance prior to the start of the
measurements. Locomotor activity was measured as horizontal (k) and vertical beam breaks counts (l). m Fasting glucose. n Fasting insulin determined
in week 16 of the diets. o–p Area under the curve (AUC) determination of Glucose tolerance tests (GTT) conducted in week 6 of the diet (o) and Insulin
tolerance tests (ITT) conducted in week 10 of the diets (p). q–r, Glucose concentration measurements during the GTT (q) and ITT (r). Mice were injected
i.p. glucose 1 g/kg (q) or Insulin 0.5 IU/kg (r). Data were analyzed by two-way ANOVA (a–p) or two-way RM ANOVA (q, r) followed by Bonferroni post-
tests (*, p < 0.05; **, p < 0.01; ***, p < 0.001) or by t test (f) (#, p < 0.05). The number of male offspring in each group was n = 5–9 originating from at least
three different dams. All data are expressed as mean ± SEM. HFD intake effectively rendered mice obese, diabetic and hypoactive (a–i, k–p: p < 0.005,
HFD vs. STD, two-way ANOVA)
Table 1 Plasma lipids
Lipid (mg/dl) Nicotine STD Control STD Nicotine HFD Control HFD
Triglycerides 48.1 ± 5.4 44.6 ± 4.1 61.9 ± 5.4 67.0 ± 3.0*
Cholesterol 67.5 ± 3.1 64.7 ± 1.4 156.5 ± 12.3** 166.8 ± 4.7**
HDL-Cholesterol 50.6 ± 3.6 48.9 ± 1.3 124.3 ± 3.0** 125.9 ± 1.6**
VLDL-Cholesterol 9.6 ± 1.2 8.9 ± 0.8 12.4 ± 1.0 13.4 ± 0.6*
LDL-Cholesterol 5.2 ± 0.9 7.2 ± 1.1 27.3 ± 4.4** 27.5 ± 3.8**
Plasma lipids were determined in week 16 of the diets following 14 h overnight fasting using VITROS® technology. Data were analyzed by two-way ANOVA
followed by Bonferrroni post-test (*, p < 0.01; **, p < 0.001 versus STD feeding). Each group consisted of n = 6–9 male offspring from at least three different dams.
Data are expressed as mean ± SEM. HDL High density lipoprotein, LDL Low density lipoprotein, VLDL Very low density lipoprotein
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sensitivity of HFD offspring to feeding inhibition by leptin
1 h after refeeding (t14 = 2.11, p = 0.054; t test) (Fig. 3d).
MTII administration examined the response of second
order signaling neurons controlling food intake and
body weight including those innervated by hypothalamic
POMC neurons. PNE tended to decrease body weight
gain of MTII-injected and vehicle-injected offspring on
the STD (t = 4 h: F1,29 = 2.9, p = 0.099; t = 8 h: F1,29 = 2.89,
p = 0.099; two-way ANOVA) (Fig. 3e) and HFD (t = 2 h:
F1,28 = 5.3, p = 0.03; t = 4 h: F1,28 = 18.96, p < 0.0001; t =
8 h: F1,28 = 9.3, p = 0.005; two-way ANOVA) (Fig. 3f). PNE
and control offspring on the STD were equally sensitive to
MTII-induced body weight loss (Fig. 3e). Under HFD
conditions, PNE offspring were more sensitive to MTII-
induced body weight loss than control offspring (t = 4 h:
p < 0.05; t = 24 h: p < 0.05; Bonferroni post-test) (Fig. 3f).
As we observed during the leptin sensitivity experiments,









































































































































































































































































Fig. 3 PNE decreased body weight gain and moderately increased sensitivity to leptin-induced and melanotan II (MTII)-induced body weight loss
of offspring in refeeding experiments. Male offspring were fasted for 12 h, injected i.p. leptin (5 mg/kg), MTII (5 mg/kg), or vehicle (PBS), and immediately
offered food. Body weight gain (% of pre-injection body weight) and food intake were determined at defined time points post injection. a–d Leptin
experiments: body weight change of STD mice (a) and HFD mice (b), cumulative food intake of STD mice (c) and HFD mice (d). e–h MTII
experiments: body weight change of STD mice (e) and HFD mice (f), cumulative food intake of STD mice (g) and HFD mice (h). Data
were analyzed by two-way ANOVA followed by Bonferroni post-tests (*, p < 0.05; **, p < 0.01; ***, p < 0.001) or unpaired two-tailed t test: (#, p < 0.05
and numerical p values in b and d). The number of male offspring in each group was n = 7–9 originating from at least three different dams. All data
are expressed as mean ± SEM
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than vehicle-injected control offspring under STD condi-
tions (t = 4 h: p < 0.05; t = 8 h: p < 0.05; Bonferroni post-
test) (Fig. 3e) and HFD conditions (t = 4 h: p < 0.05; t =
8 h: p < 0.01; Bonferroni post-test) (Fig. 3f ). Finally, PNE
tended to moderately decrease food consumption of
MTII-injected and vehicle-injected offspring on the STD
(t = 4 h: F1,29 = 5.1, p = 0.03; t = 8 h: F1,29 = 3.8, p = 0.06;
two-way ANOVA) (Fig. 3g) and HFD (t = 4 h: F1,28 = 6.2,
p = 0.02; t = 8 h: F1,28 = 3.4, p = 0.08; two-way ANOVA)
(Fig. 3h).
In summary, the refeeding experiments showed that
PNE decreased body weight gain of offspring and ren-
dered them moderately more sensitive to the acute body
weight lowering effects of leptin and MTII.
Most human obesity and animal models of diet-
induced obesity are associated with elevated plasma
leptin levels [50–52], and the development of resistance
to leptin’s body weight lowering actions [5]. Therefore,
we measured plasma leptin concentrations as an indica-
tor for hypothalamic leptin resistance. Plasma leptin
concentrations were the same in PNE and control off-
spring on the STD (PNE: 0.9 ± 0.09 ng/ml, n = 7; control:
0.98 ± 0.18 ng/ml, n = 9) but they were decreased in PNE
offspring under HFD conditions (PNE, 9.3 ± 1.07 ng/ml,
n = 9; control, 14.85 ± 2.21 ng/ml, n = 7; p < 0.01 by
Bonferroni post-test) (Fig. 4a). These results further sug-
gest that PNE rendered offspring moderately more sensi-
tive to leptin.
Leptin resistance is at least in part caused by impaired
leptin signaling in the hypothalamus, including the
POMC neurons [5, 52, 53]. To further examine whether
PNE enhanced hypothalamic leptin signaling, we deter-
mined STAT3 phosphorylation (P-STAT3) in hypothal-
amic arcuate neurons 30 min after leptin i.p. injection.
P-STAT3 immunoreactivity was assessed using a rabbit
monoclonal (Fig. 4c) or a mouse monoclonal antibody
recognizing STAT3 Tyr705 phosphorylation (Fig. 4d). P-
STAT3 immunoreactivity was detected mainly in the
hypothalamic arcuate nucleus (ARC) and to a minor ex-
tent in the ventromedial hypothalamic nucleus (VMH).
Vehicle-injected offspring showed no P-STAT3 immuno-
reactivity in ARC and VMH consistent with previous ob-
servations [54, 55]. Leptin-injected PNE offspring showed
a higher number of P-STAT3 positive arcuate neurons
(mouse monoclonal P-STAT3 antibody: 31.1 ± 3.4/section
versus 8.02 ± 3.01/section, n = 3, t4 = 5.1, p = 0.007, t test;
rabbit monoclonal P-STAT3 antibody: 34.5 ± 1.3/section
versus 13.7 ± 5.6/section, n = 3, t4 = 3.66, p = 0.02, t test)
and tended to have a higher number of P-STAT3 positive
POMC neurons (9.8 ± 3.4/section versus 3.02 ± 1.6/sec-
tion, n = 3, t4 = 1.8, p = 0.14, t test) than leptin-injected
control offspring (Fig. 4e, f, g). In PNE offspring, P-STAT3
reactivity was almost exclusively detected in the cell nuclei
(Fig. 4c, d). In control offspring, P-STAT3 reactive nuclei
were less intensely stained (Fig. 4c, d) and many cells with
cytoplasmic P-STAT3 staining were detected in con-
trast to PNE offspring (Fig. 4c). These findings sug-
gest that PNE offspring respond faster to leptin-
induced cytoplasmic-nuclear translocation of P-STAT3
and are consistent with enhanced hypothalamic leptin-
signaling in PNE offspring.
Leptin stimulates P-STAT3 mediated transcription of
POMC. To further determine the long-term effects of
PNE on leptin signaling, we determined the levels of
hypothalamic POMC mRNA at the end of the 16-week
diet. PNE moderately increased POMC mRNA of adult
male offspring under HFD but not under STD condi-
tions (F1,28 = 6.7, p = 0.015 by two-way ANOVA; p < 0.05
by Bonferroni post-test) (Fig. 4b) consistent with en-
hanced leptin-melanocortin signaling.
Characterization of the coding and long non-coding
transcriptome of hypothalamic POMC neurons
Hypothalamic POMC neurons were isolated by laser mi-
crodissection from six prenatally nicotine-exposed and
five non-exposed, STD-fed adult male offspring express-
ing the enhanced green fluorescent protein in POMC
neurons [40]. A range of 400–600 POMC neurons were
isolated from each mouse brain. Strand-specific RNA-
seq libraries were generated from these POMC neurons.
A selective priming method during first strand cDNA
synthesis minimized reverse transcription of ribosomal
RNA (rRNA) sequences. Libraries were paired-end se-
quenced on Illumina’s HiSeq2000 sequencer. Read-pairs
were aligned to the mouse reference mm10 genome
using STAR [41]. Only read-pairs aligning to a unique
site of the mouse genome with less than two mismatches
were used for analysis. Aligned read-pairs were run
through HTSeq against the GENCODE reference gtf file
vM4 for determination of read-pair counts by genes
under consideration of DNA strand specificity [42]. Ex-
pression of a gene was normalized by dividing the num-
ber of read-pairs mapped to its exons by the number of
read-pairs mapped to the reference genome. The result-
ing value was expressed in counts per million (CPM). In-
dividual expression levels of alternative transcript
variants were not quantified. For all analyses, only genes
with average expression values across all samples > 1
CPM were considered. Three expression calculators in
edgeR [43], DESeq [44], and baySeq [45] determined dif-
ferential gene expression. The intersection of differen-
tially expressed features across these three calculators
yielded the final list of differentially expressed genes.
Each library yielded on average 42.9 million read-pairs
passing Illumina’s quality control filters (PNE: 46.3 mil-
lion; control: 38.8 million). On average, 30 million or
70.5 % read-pairs per library were aligned to unique sites
of the reference genome (PNE: 32.7 million or 71.3 %;















































































































































































Fig. 4 (See legend on next page.)
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Control: 26.8 million or 69.4 %) (Table 2). Read-pairs
mapped to 16,014 genes with average expression levels >
1 CPM (Additional file 1: Table S1). Of these, 13,539
(84.5 %) were protein-coding genes, 1708 (10.7 %) were
ncRNA genes, and 767 (4.8 %) were pseudogenes
(Fig. 5a). NcRNA genes comprised 1124 (65.8 %)
lncRNA genes, 265 (15.5 %) short ncRNA genes, and
319 (18.7 %) processed transcripts (Fig. 5b). Mapped
lncRNA genes comprised 509 (45.3 %) lincRNA genes,
551 (49 %) antisense RNA genes, 59 (5.2 %) sense-
intronic RNA genes, four (0.4 %) sense-overlapping
RNA genes, and one (0.1 %) 3′-overlapping ncRNA gene
(Fig. 5c). Mapped short ncRNA genes were composed of
116 (43.8 %) microRNA (miRNA) genes, 81 (30.6 %)
small nucleolar RNA (snoRNAs) genes, 20 (7.5 %) small
nuclear RNA (snRNA) genes, ten (3.8 %) rRNA genes,
and 38 (14.3 %) miscellaneous RNA (miscRNA) genes
(Fig. 5d). The fraction of expressed short ncRNA genes
is likely underestimated because the RNA isolation pro-
cedure excluded RNAs smaller than 100 nucleotides.
Antisense RNA genes expressed at levels > 1 CPM were
almost exclusively non-coding (551 or 99.8 %) and
overlapped 529 (87.4 %) protein-coding genes, 61
(10.1 %) ncRNA genes, and 15 (2.5 %) pseudogenes
(Fig. 5f ).
A total of 13,534 protein-coding genes with average
expression levels > 1 CPM were subjected to gene ontol-
ogy (GO) classification using the PANTHER gene
analysis tool [46]. PANTHER classified 12,731 protein-
coding genes by molecular function, biological process,
protein class, cellular component, and pathway. Most
genes had binding (3817; 33.1 %), catalytic (3763;
32.7 %), and transcription factor activity (1097; 9.5 %)
(Table 3), were involved in a metabolic (5775; 50.1 %)
and cellular process (3721; 32.3 %) (Table 4), encoded
nucleic acid binding proteins (1703; 14.8 %) and tran-
scription factors (1110; 9.6 %) (Table 5), and were associ-
ated with organelles (679; 5.9 %) and macromolecular
complexes (437; 3.8 %) (Table 6). GO classification by
pathway detected the existence of numerous signaling
and neurodevelopment pathways in hypothalamic
POMC neurons (Fig. 6; Table 7; Additional file 2:
Table S2). As expected, we found expression of 19
and 17 genes participating in the opioid proopiomelano-
cortin and enkephalin release pathways, respectively
(Additional file 2: Table S2). Moreover, RNA-seq re-
vealed expression of 40 genes participating in the nic-
otinic acetylcholine receptor signaling pathway including
genes encoding the neuronal acetylcholine receptor sub-
unit α-4 (Chrna4), consistent with a previous report [10],
the neuronal acetylcholine receptor subunit α -1 (Chrna1),
α-7 (Chrna7), β-1 (Chrnb1), β-2 (Chrnb2), and acetyl-
cholinesterase (Ache) (Additional file 2: Table S2).







N1 39,371,421 28,694,853 72.9
N2 33,778,273 23,411,127 69.3
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Six PNE offspring (denoted as N1–N6) and five control offspring (denoted as
C1–C5) were paired-end sequenced on Illuminas HiSeq2000 sequencer. Read-
pairs passing Illumina’s internal quality filters (Input read-pairs) were aligned to
the mouse mm10 reference genome using STAR [41]. Read-pairs mapped to a
unique site of the mouse mm10 reference genome with less than two mismatches
(Uniquely mapped read-pairs) were used for further analyses
(See figure on previous page.)
Fig. 4 PNE enhanced hypothalamic leptin signaling in offspring. a Plasma leptin determined in week 16 of the diets. b Hypothalamic POMC
mRNA levels were determined in week 16 of the diets by reverse transcription quantitative PCR, normalized to β-actin mRNA and expressed relative to
the STD-fed control group. The number of male offspring in each group in (a) and (b) was n = 7–9 originating from at least three different
dams. c, d Leptin-induced nuclear STAT3 phosphorylation (P-STAT3) of hypothalamic arcuate nucleus neurons (c, d) and hypothalamic POMC
neurons (d) determined in STD-fed mice by immunofluorescence using antibodies against STAT3-Tyr 705 phosphorylation and POMC polypeptide.
P-STAT3 was detected using either a rabbit monoclonal (c) or mouse monoclonal antibody (d, left panel). Male offspring were fasted for 14 h, injected
i.p. leptin (5 mg/kg), and sacrificed 30 min post injection. White arrows highlight several P-STAT3 reactive nuclei in the hypothalamic arcuate nucleus
(ARC) (c, d, left panel), POMC positive neurons (d, middle panel), and POMC positive neurons with P-STAT3 reactive nuclei (d, right panel). Red arrows
highlight neurons with cytoplasmic P-STAT3 immunoreactivity (c, right panel). 3 V refers to the third ventricle (c, d). The size bars represent 50 μM
(c, d). e, f Quantification of leptin-induced nuclear STAT3 phosphorylation in hypothalamic arcuate neurons after staining with rabbit monoclonal P-STAT3
antibody (e) or mouse monoclonal P-STAT3 antibody (f) (n= 3 male offspring per group). g Quantification of P-STAT3 immunoreactive hypothalamic
POMC neurons (n= 3 male offspring per group). Data were analyzed by two-way ANOVA followed by Bonferroni post-tests (*, p < 0.05; **,
p < 0.01; ***, p < 0.001) (a, b) or by two-tailed t test (e, f). All data are expressed as mean ± SEM
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We also detected expression of various G-protein
coupled receptor-signaling pathways that were previ-
ously reported to regulate feeding and body weight, to
be expressed in POMC neurons and/or to regulate
POMC neuronal activity. These included the dopamin
receptor [56], oxytocin receptor [57], metabotropic glu-
tamate receptor I-III [58, 59], ionotropic glutamate re-
ceptor, histamine H1/H2 receptor [60], serotonin 1–4
(5HT1-4) receptor [61], GABA-B receptor II [62, 63], α-
adrenoceptor [64], β1-3 adrenoceptor, and muscarinic
acetylcholine receptor 1–4 pathways [65] (Fig. 6; Table 7;
Additional file 2: Table S2).
POMC neurons expressed a synaptic vesicle trafficking
pathway (Fig. 6; Table 7; Additional file 2: Table S2), the
vesicular glutamate transporter 2 (vGlut2 or Slc17a6)
and vesicular GABA transporter (vGat or Slc32a1), me-
diating uptake of glutamate and GABA/glycine into syn-
aptic vesicles, respectively (Additional file 1: Table S1).
Moreover, we found expression of the insulin/insulin
like growth factor (Igf ) /protein kinase B (Akt), insulin/
Igf/mitogen activated protein kinase kinase (Mapkk)/
mitogen activated protein kinase (Mapk), and Jak/Stat
signaling pathways in hypothalamic POMC neurons
(Fig. 6; Table 7; Additional file 2: Table S2). RNA-seq
also revealed expression of three key genes of the leptin
receptor signaling pathway, the leptin receptor (Lepr),
Jak2 and Stat3 genes, and regulators of the leptin signal-
ing pathway including suppressor of cytokine signaling 3
(Socs3) and protein tyrosine phosphatase 1 b (Ptpn1)
(Additional file 1: Table S1).
POMC neurons also expressed various neuroendocrine-
signaling pathways. These included the thyrotropin-
releasing hormone (TRH) receptor, cortocotropin releasing
factor (CRF) receptor, and gonadotropin releasing hormone
(GnRH) receptor signaling pathways (Fig. 6; Table 7;
Additional file 2: Table S2). Moreover, we found expres-
sion of the fibroblast growth factor (FGF) signaling path-
way and several fibroblast growth factors including Fgf1,
Fgf9, Fgf12, Fgf13, and Fgf14 (Fig. 6; Table 7; Additional
file 2: Table S2). POMC neurons also expressed several
genes encoding core components of the circadian clock
(Fig. 6; Table 7; Additional file 2: Table S2).
POMC neurons further expressed several neurodeve-
lopment pathways. These included the netrin, Slit/Robo,
a b c
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Fig. 5 Composition of the transcriptome of hypothalamic POMC neurons by total RNA (a), ncRNA (b), lncRNA (c), short ncRNA (d), antisense RNA
(e), and sense RNA (complementary to antisense RNA) (f). Only RNAs expressed at levels > 1 CPM were considered for analyses
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and semaphorin axon guidance pathways, as well as the
wnt, cadherin, integrin, transforming growth factor
(TGF)-β, platelet derived growth factor (PDGF), and epi-
dermal growth factor (EGF) pathways (Fig. 6; Table 7;
Additional file 2: Table S2). Finally, RNA-seq detected
expression of the Notch signaling and Alzheimer amyl-
oid secretase pathways (Fig. 6; Table 7; Additional file 2:
Table S2).
We ranked 1119 lncRNA genes (509 lincRNA, 551
antisense RNA, and 59 sense-intronic RNA genes)
expressed at levels > 1 CPM by expression (Additional
file 3: Table S3). Of these, Yam1, Malat1, Meg3,
Gm26870, Gm15564, 6330403K07Rik, Kcnq1ot1, Miat,
A330023F24Rik, and Gm14703 were the most abun-
dantly expressed lncRNAs (Additional file 3: Table S3).
LncRNAs can regulate coding genes in cis through epi-
genetic, transcriptional, and post-transcriptional mech-
anism. To gain explorative insight into potential gene
regulatory functions of lncRNAs expressed in POMC
neurons, we assessed linear co-expression of lncRNAs
(antisense RNA, lincRNA, sense-intronic RNA) with
their nearest (adjacent or overlapping) protein-coding
gene applying an expression threshold of 1 CPM for both,
coding and non-coding gene expression. A Pearson’s cor-
relation coefficient r > 0.602 or < −0.602 (n = 11, p < 0.05 by
two-tailed t test) was regarded as significant. A total of
1053 lncRNA genes (452 lincRNA, 548 antisense RNA,
and 53 sense-intronic RNA genes) and 991 protein-coding
genes forming 1096 lncRNA/coding gene pairs were exam-
ined. We detected 82 co-expressed lncRNA/coding gene
pairs comprising 41 antisense RNA/coding gene pairs, 34
lincRNA/coding gene pairs, and seven sense-intronic
RNA/coding gene pairs (Additional file 4: Table S4). 59 (or
72 %) lncRNA/protein-coding gene pairs were positively
co-expressed whereas 23 (or 28 %) were negatively (dis-
cordantly) co-expressed. In over 75 % of the co-expressed
lncRNA/coding gene pairs, expression level of the lncRNA
was less than 30 % that of the coding gene. In the majority,
65 or 79 %, of lncRNA/coding gene pairs, the lncRNA
overlapped the coding gene. Furthermore, in 29 or 35 % of
lncRNA/coding gene pairs, the lncRNA overlapped the
coding gene promoter spanning the 10 kb sequence up-
stream of its first exon (Additional file 4: Table S4).
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PANTHER classified 12,731 protein-coding genes with average expression
values > 1 CPM by biological process. A total of 21,970 biological processes
were hit
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PANTHER classified 12,731 protein-coding genes with average expression
values > 1 CPM by molecular function. A total of 13,395 molecular functions
were hit
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Since lncRNAs can be transcribed from enhancers as
so-called enhancer RNAs (eRNAs) to stimulate gene
transcription [66, 67], we determined whether lncRNAs
that were co-expressed with their nearest protein-coding
genes were transcribed from conserved mouse en-
hancers annotated in the VISTA enhancer browser data-
base [68]. Only one lncRNA, Gm16263, an antisense
RNA to the co-expressed protein-coding gene Fgf10, was
transcribed from an annotated mouse enhancer. This
enhancer spanned a region 1089 nucleotides upstream
and 313 nucleotides downstream of the transcription
start site of Fgf10 (mm10 build, chr13:118713610–
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Table 5 Gene Ontology classification of protein-coding genes
by protein class (Continued)
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PANTHER classified 12,731 protein-coding genes with average expression
values > 1 CPM by protein class. A total of 13,887 protein classes were hit
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118715012), thus overlapping the Fgf10 gene promoter
and a small fragment of exon1 of Fgf10.
Co-expressed protein-coding genes had functions in
nervous system development (Irx3, Msi2, Lhx1, Sox4,
Plcb1), neurite outgrowth (Farp1, Lhx1, Ppp1r9a, Rap-
gef4, Srgap2), synaptogenesis (Cep112, Farp1, Fgf10,
Myo6), neurotransmission (Hrh3, Gabra5, Plcb1, Rap-
gef4, Myo6, Kcna3, Kcna6, Kcnmb4), intracellular Ca2+
signaling (Pitpnm2, Slc8a3, Plcb1), insulin signaling (Irs4,
Plcb1, Aspscr1, Baiap2l1), mitochondrial biogenesis,
ubiquitin-dependent protein degradation, transcription
regulation, RNA processing, cell cycle, cell division, cell
growth, cell differentiation, cell adhesion, organization of
the cytoskeleton, and apoptosis (Additional file 4: Table S4).
Nineteen lncRNAs (A330102I10Rik, B930095G15Rik,
Cep112os2, C030037D09Rik, Gm2727, Gm9962, Gm16006,
Gm16263, Gm17180, Gm26673, Gm26814, Gm27008,
Irx3os, Kcnmb4os1, Lhx1os, Rapgef4os3, RP24-302 F18.2,
9630028H03Rik, 2210017G18Rik) were co-expressed with
the above-mentioned coding genes regulating nervous sys-
tem development and function (Additional file 4: Table S4).
Prenatal nicotine upregulates Gm15851 in adult offspring
hypothalamic POMC neurons
The intersection of the results of three differential ex-
pression calculators, edgeR, baySeq, and DESeq, revealed
only one consistent expression difference between
nicotine-exposed and non-exposed offspring, an 80-fold
upregulation of Gm15851 in PNE offspring (FDR-ad-
justed p value: 0.006 by edgeR, 0.002 by baySeq and
DESeq; average expression level: 4.5 CPM). Two-way
clustering revealed overlapping gene expression signa-
tures of prenatally nicotine-exposed and non-exposed
hypothalamic POMC neurons (Fig. 7a). Quantitative re-
verse transcription polymerase chain reaction (qRT-
PCR) confirmed upregulation of Gm15851 in POMC
neurons of nicotine-exposed offspring (t5 = 3.17, p =
0.025 by t test with Welch’s correction) (Fig. 7b).
Gm15851 is a lncRNA of 662 nucleotides encoded by
three exons on the forward strand of chromosome 1
(Fig. 7c). Supporting evidence for the existence of this
transcript comes from one expressed sequence tag in the
adult mouse male epididymis cDNA RIKEN full-length
enriched library (RIKEN clone 9230112 L10) [21].
Gm15851 lacks a significant open reading frame. It is an
antisense RNA overlapping two protein-coding genes,
opticin (Optc) and proline arginine-rich end leucine-rich
repeat (Prelp), on the reverse strand. The third exon of
Gm15851 overlaps the second coding exon of Prelp
whereas the first exon of Gm15851 overlaps the
first intron of Optc (Fig. 7c). Although Optc and Prelp
are potential targets of cis-regulation by Gm15851,
both genes were not co-expressed with Gm15851 in
POMC neurons.
Discussion
Contrary to expectations based on previous studies of
gestational and neonatal nicotine exposure and energy
balance, we report here that gestational nicotine expos-
ure does not render offspring more susceptible to diet-
induced obesity or type 2 diabetes. Instead, we found
that gestational nicotine exposure moderately decreased
food intake, body weight gain, and glycemia, and mildly
increased sensitivity to leptin and melanocortin receptor
stimulation in first-generation adult offspring. Consistent
with a moderate enhancement in leptin sensitivity, PNE
offspring were more sensitive to leptin-induced STAT3
phosphorylation, and—under HFD conditions—had in-
creased POMC mRNA and decreased plasma leptin con-
centrations. Consistent with previous reports [35, 69],
PNE offspring displayed increased voluntary locomotor
activity under HFD conditions, which could reflect aug-
mented exploratory behavior [69] or might result from
enhanced central leptin-melanocortinergic signaling via
POMC neurons as others and we have reported [6, 70].
Interestingly, although food intake was moderately de-
creased and voluntary locomotion moderately increased
under HFD feeding conditions, overall energy balance
was unaffected in PNE offspring since neither body
weights nor body fat content nor energy expenditure
were measurably changed. It is possible that altered cen-
tral regulation of body temperature in PNE offspring
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PANTHER classified 12,731 protein-coding genes with average expression
values > 1 CPM by cellular component. Protein-coding genes hit a total of
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accounts for this outcome. Impaired central activation of
brown fat thermogenesis could lead to compensatory
hyperlocomotion to increase heat expenditure and pre-
serve body temperature. Yet another possibility is that
metabolic efficiency—the degree to which ingested food
is being metabolized to perform work and generate
heat—could be increased in PNE offspring. These alter-
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Fig. 6 Assignment of expressed genes to PANTHER defined pathways. The PANTHER pathway accession numbers and the number of mapped
genes are indicated. Only genes expressed at levels > 1 CPM were considered
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Table 7 Gene Ontology classification of protein-coding genes by pathway
Category name (PANTHER pathway accession number) Number of
gene hits
Percent of gene hit against
total number of genes
Percent of gene hit against total
number of pathway hits
2-arachidonoylglycerol biosynthesis (P05726) 4 0.00 % 0.10 %
5-Hydroxytryptamine biosynthesis (P04371) 2 0.00 % 0.00 %
5-Hydroxytryptamine degradation (P04372) 3 0.00 % 0.10 %
5HT1 type receptor mediated signaling pathway (P04373) 25 0.20 % 0.60 %
5HT2 type receptor mediated signaling pathway (P04374) 39 0.30 % 1.00 %
5HT3 type receptor mediated signaling pathway (P04375) 12 0.10 % 0.30 %
5HT4 type receptor mediated signaling pathway (P04376) 16 0.10 % 0.40 %
Acetate utilization (P02722) 3 0.00 % 0.10 %
Activin-beta signaling pathway (P06210) 3 0.00 % 0.10 %
Adenine and hypoxanthine salvage pathway (P02723) 6 0.10 % 0.10 %
Adrenaline and noradrenaline biosynthesis (P00001) 22 0.20 % 0.50 %
Alanine biosynthesis (P02724) 2 0.00 % 0.00 %
ALP23B_signaling_pathway (P06209) 3 0.00 % 0.10 %
Alpha adrenergic receptor signaling pathway (P00002) 20 0.20 % 0.50 %
Alzheimer disease-amyloid secretase pathway (P00003) 50 0.40 % 1.20 %
Alzheimer disease-presenilin pathway (P00004) 74 0.60 % 1.80 %
Aminobutyrate degradation (P02726) 2 0.00 % 0.00 %
Androgen/estrogene/progesterone biosynthesis (P02727) 3 0.00 % 0.10 %
Angiogenesis (P00005) 125 1.10 % 3.10 %
Angiotensin II-stimulated signaling through G proteins and
beta-arrestin (P05911)
30 0.30 % 0.70 %
Apoptosis signaling pathway (P00006) 80 0.70 % 2.00 %
Arginine biosynthesis (P02728) 4 0.00 % 0.10 %
Ascorbate degradation (P02729) 2 0.00 % 0.00 %
Asparagine and aspartate biosynthesis (P02730) 4 0.00 % 0.10 %
ATP synthesis (P02721) 6 0.10 % 0.10 %
Axon guidance mediated by netrin (P00009) 29 0.30 % 0.70 %
Axon guidance mediated by semaphorins (P00007) 18 0.20 % 0.40 %
Axon guidance mediated by Slit/Robo (P00008) 18 0.20 % 0.40 %
B cell activation (P00010) 49 0.40 % 1.20 %
Beta1 adrenergic receptor signaling pathway (P04377) 26 0.20 % 0.60 %
Beta2 adrenergic receptor signaling pathway (P04378) 26 0.20 % 0.60 %
Beta3 adrenergic receptor signaling pathway (P04379) 11 0.10 % 0.30 %
Blood coagulation (P00011) 22 0.20 % 0.50 %
BMP_signaling_pathway-drosophila (P06211) 2 0.00 % 0.00 %
Cadherin signaling pathway (P00012) 103 0.90 % 2.50 %
Carnitine and CoA metabolism (P02732) 1 0.00 % 0.00 %
Carnitine metabolism (P02733) 1 0.00 % 0.00 %
Cell cycle (P00013) 17 0.10 % 0.40 %
Cholesterol biosynthesis (P00014) 9 0.10 % 0.20 %
Circadian clock system (P00015) 9 0.10 % 0.20 %
Coenzyme A biosynthesis (P02736) 6 0.10 % 0.10 %
Cortocotropin releasing factor receptor signaling pathway (P04380) 27 0.20 % 0.70 %
Cysteine biosynthesis (P02737) 1 0.00 % 0.00 %
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Table 7 Gene Ontology classification of protein-coding genes by pathway (Continued)
Cytoskeletal regulation by Rho GTPase (P00016) 57 0.50 % 1.40 %
De novo purine biosynthesis (P02738) 19 0.20 % 0.50 %
De novo pyrimidine deoxyribonucleotide biosynthesis (P02739) 6 0.10 % 0.10 %
De novo pyrmidine ribonucleotides biosythesis (P02740) 8 0.10 % 0.20 %
DNA replication (P00017) 19 0.20 % 0.50 %
Dopamine receptor mediated signaling pathway (P05912) 48 0.40 % 1.20 %
DPP_signaling_pathway (P06213) 2 0.00 % 0.00 %
DPP-SCW_signaling_pathway (P06212) 2 0.00 % 0.00 %
EGF receptor signaling pathway (P00018) 101 0.90 % 2.50 %
Endogenous_cannabinoid_signaling (P05730) 18 0.20 % 0.40 %
Endothelin signaling pathway (P00019) 65 0.60 % 1.60 %
Enkephalin release (P05913) 17 0.10 % 0.40 %
FAS signaling pathway (P00020) 24 0.20 % 0.60 %
FGF signaling pathway (P00021) 86 0.70 % 2.10 %
Flavin biosynthesis (P02741) 2 0.00 % 0.00 %
Folate biosynthesis (P02742) 2 0.00 % 0.00 %
Formyltetrahydroformate biosynthesis (P02743) 4 0.00 % 0.10 %
Fructose galactose metabolism (P02744) 9 0.10 % 0.20 %
GABA-B_receptor_II_signaling (P05731) 30 0.30 % 0.70 %
Gamma-aminobutyric acid synthesis (P04384) 5 0.00 % 0.10 %
GBB_signaling_pathway (P06214) 2 0.00 % 0.00 %
General transcription by RNA polymerase I (P00022) 13 0.10 % 0.30 %
General transcription regulation (P00023) 30 0.30 % 0.70 %
Glutamine glutamate conversion (P02745) 2 0.00 % 0.00 %
Glycolysis (P00024) 18 0.20 % 0.40 %
Gonadotropin releasing hormone receptor pathway (P06664) 185 1.60 % 4.60 %
Hedgehog signaling pathway (P00025) 19 0.20 % 0.50 %
Heme biosynthesis (P02746) 8 0.10 % 0.20 %
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha
mediated pathway (P00026)
103 0.90 % 2.50 %
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha
mediated pathway (P00027)
86 0.70 % 2.10 %
Heterotrimeric G-protein signaling pathway-rod outer segment
phototransduction (P00028)
17 0.10 % 0.40 %
Histamine H1 receptor mediated signaling pathway (P04385) 22 0.20 % 0.50 %
Histamine H2 receptor mediated signaling pathway (P04386) 9 0.10 % 0.20 %
Huntington disease (P00029) 112 1.00 % 2.80 %
Hypoxia response via HIF activation (P00030) 21 0.20 % 0.50 %
Inflammation mediated by chemokine and cytokine signaling
pathway (P00031)
135 1.20 % 3.30 %
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP
kinase cascade (P00032)
26 0.20 % 0.60 %
Insulin/IGF pathway-protein kinase B signaling cascade (P00033) 30 0.30 % 0.70 %
Integrin signalling pathway (P00034) 135 1.20 % 3.30 %
Interferon-gamma signaling pathway (P00035) 24 0.20 % 0.60 %
Interleukin signaling pathway (P00036) 59 0.50 % 1.50 %
Ionotropic glutamate receptor pathway (P00037) 41 0.40 % 1.00 %
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Table 7 Gene Ontology classification of protein-coding genes by pathway (Continued)
Isoleucine biosynthesis (P02748) 3 0.00 % 0.10 %
JAK/STAT signaling pathway (P00038) 15 0.10 % 0.40 %
Leucine biosynthesis (P02749) 2 0.00 % 0.00 %
Lipoate_biosynthesis (P02750) 2 0.00 % 0.00 %
Mannose metabolism (P02752) 5 0.00 % 0.10 %
Metabotropic glutamate receptor group I pathway (P00041) 19 0.20 % 0.50 %
Metabotropic glutamate receptor group II pathway (P00040) 25 0.20 % 0.60 %
Metabotropic glutamate receptor group III pathway (P00039) 45 0.40 % 1.10 %
Methionine biosynthesis (P02753) 2 0.00 % 0.00 %
Methylcitrate cycle (P02754) 2 0.00 % 0.00 %
Methylmalonyl pathway (P02755) 3 0.00 % 0.10 %
mRNA splicing (P00058) 6 0.10 % 0.10 %
Muscarinic acetylcholine receptor 1 and 3 signaling pathway (P00042) 38 0.30 % 0.90 %
Muscarinic acetylcholine receptor 2 and 4 signaling pathway (P00043) 29 0.30 % 0.70 %
P53 pathway feedback loops 1 (P04392) 5 0.00 % 0.10 %
P53 pathway feedback loops 2 (P04398) 41 0.40 % 1.00 %
Parkinson disease (P00049) 74 0.60 % 1.80 %
PDGF signaling pathway (P00047) 105 0.90 % 2.60 %
Pentose phosphate pathway (P02762) 7 0.10 % 0.20 %
Phenylethylamine degradation (P02766) 1 0.00 % 0.00 %
PI3 kinase pathway (P00048) 40 0.30 % 1.00 %
Plasminogen activating cascade (P00050) 3 0.00 % 0.10 %
PLP biosynthesis (P02759) 1 0.00 % 0.00 %
Proline biosynthesis (P02768) 4 0.00 % 0.10 %
Purine metabolism (P02769) 7 0.10 % 0.20 %
Pyridoxal phosphate salvage pathway (P02770) 1 0.00 % 0.00 %
Pyrimidine Metabolism (P02771) 8 0.10 % 0.20 %
Pyruvate metabolism (P02772) 6 0.10 % 0.10 %
Ras Pathway (P04393) 61 0.50 % 1.50 %
S adenosyl methionine biosynthesis (P02773) 2 0.00 % 0.00 %
Salvage pyrimidine deoxyribonucleotides (P02774) 1 0.00 % 0.00 %
Salvage pyrimidine ribonucleotides (P02775) 6 0.10 % 0.10 %
SCW_signaling_pathway (P06216) 2 0.00 % 0.00 %
Serine glycine biosynthesis (P02776) 5 0.00 % 0.10 %
Succinate to proprionate conversion (P02777) 2 0.00 % 0.00 %
Sulfate assimilation (P02778) 2 0.00 % 0.00 %
Synaptic_vesicle_trafficking (P05734) 24 0.20 % 0.60 %
T cell activation (P00053) 58 0.50 % 1.40 %
TCA cycle (P00051) 9 0.10 % 0.20 %
TGF-beta signaling pathway (P00052) 62 0.50 % 1.50 %
Thiamine metabolism (P02780) 3 0.00 % 0.10 %
Threonine biosynthesis (P02781) 2 0.00 % 0.00 %
Thyrotropin-releasing hormone receptor signaling pathway (P04394) 35 0.30 % 0.90 %
Toll receptor signaling pathway (P00054) 39 0.30 % 1.00 %
Toll_pathway_drosophila (P06217) 1 0.00 % 0.00 %
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Furthermore, it remains to be clarified whether PNE has
sexually dimorphic effects on the regulation of energy bal-
ance in offspring. Recently, Burke et al. reported that a
subpopulation of hypothalamic arcuate POMC neurons,
which express 5-hydroxytryptamine 2c receptors (5-
HT2CRs) and account for 40 % of all hypothalamic arcu-
ate POMC neurons, regulates energy balance in a sexually
dimorphic manner [71]. The authors re-expressed POMC
selectively in 5-HT2CR containing POMC neurons of
POMC-deficient obese and insulin-resistant mice. Re-
expression of POMC in this neuronal subpopulation was
sufficient to normalize food intake, physical activity,
brown fat heat expenditure, body weight, adiposity, and
insulin sensitivity in males. Meanwhile, re-expression of
POMC in this neuronal subpopulation in females cor-
rected only food intake and insulin sensitivity but did nei-
ther increase physical activity, energy expenditure nor
block the development of obesity [71].
Previous human epidemiological and meta-analysis
studies [11–14] reported a positive correlation between
PNE and the risk for obesity and type 2 diabetes in chil-
dren and young adults. This correlation was further sup-
ported by rat studies of gestational and lactational
nicotine exposure [15–18]. The onset, length, and route
of nicotine administration likely determine the cumula-
tive dose and developmental stage at which hypothal-
amic POMC neuronal progenitor cells are exposed to
nicotine. Maternal plasma cotinine levels in the present
and in previous rodent studies reporting metabolic dis-
turbances in the offspring were of similar magnitude
[15–17], suggesting that dams were exposed to compar-
able doses of nicotine. However, previous studies report-
ing diabetes in the offspring administered nicotine
subcutaneously to dams [15–17, 72]. Nicotine that is
subcutaneously administered to dams may reach the
fetus at a higher concentration than maternally ingested
nicotine because the former does not undergo first-pass
hepatic conversion to cotinine contrary to the latter. In
addition to differences in the route of administration,
gestational nicotine exposure was continued throughout
lactation in two studies reporting diabetes and obesity in
the offspring [15, 17]. Bruin et al. [72] showed that dis-
turbances in glucose homeostasis in the offspring re-
quired nicotine exposure to occur both during gestation
and lactation. This would be in line with the timing of
development of murine hypothalamic arcuate neurons,
which differentiate between embryonic days 10 and 16
[73] and form projections in the first three postnatal
weeks to other hypothalamic regions involved in feeding
regulation [74, 75]. Our observations suggest dose-
dependent and time-dependent effects of nicotine on de-
veloping hypothalamic POMC neurons. Exposure to
nicotine at a low dose during gestation might stimulate
proliferation, differentiation, neurite outgrowth, and syn-
aptogenesis of developing hypothalamic POMC neurons,
thereby sensitizing leptin-melanocortinergic signaling in
adult offspring, whereas exposure to nicotine at a high
dose during gestation and lactation might impair those
processes, leading to the reported obesity and diabetes
phenotypes in adult offspring.
RNA-seq of hypothalamic POMC neurons isolated
from adult PNE and control offspring followed by differ-
ential expression analyses using three expression calcula-
tors detected only one consistent change, a nicotine-
induced upregulation of Gm15851, an antisense RNA to
the Prelp and Optc genes. Although Gm15851 was not
co-expressed with Prelp or Optc in terminally differenti-
ated POMC neurons, we cannot exclude that cis-regula-
tory interactions between Gm15851 and Prelp or Optc
exist in POMC neuronal progenitor cells. LncRNAs may
serve as scaffolds for gene-specific recruitment of tran-
scription factors, transcriptional complexes, and/or
chromatin-modifying complexes during specific develop-
mental time windows. These additional regulators may
Table 7 Gene Ontology classification of protein-coding genes by pathway (Continued)
Transcription regulation by bZIP transcription factor (P00055) 41 0.40 % 1.00 %
Triacylglycerol metabolism (P02782) 1 0.00 % 0.00 %
Tryptophan biosynthesis (P02783) 1 0.00 % 0.00 %
Tyrosine biosynthesis (P02784) 1 0.00 % 0.00 %
Ubiquitin proteasome pathway (P00060) 50 0.40 % 1.20 %
Valine biosynthesis (P02785) 3 0.00 % 0.10 %
Vasopressin synthesis (P04395) 11 0.10 % 0.30 %
VEGF signaling pathway (P00056) 47 0.40 % 1.20 %
Vitamin B6 metabolism (P02787) 3 0.00 % 0.10 %
Vitamin D metabolism and pathway (P04396) 7 0.10 % 0.20 %
Wnt signaling pathway (P00057) 211 1.80 % 5.20 %
Xanthine and guanine salvage pathway (P02788) 4 0.00 % 0.10 %
PANTHER classified 12,731 protein-coding genes with average expression values > 1 CPM by pathway. A total of 4445 pathways were hit


























































Fig. 7 (See legend on next page.)
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not be expressed in terminally differentiated POMC neu-
rons thus preventing regulatory interactions of Gm15851
with Optc and/or Prelp to be seen. It is possible that, in
addition to regulation of transcription or chromatin state,
Gm15851 might regulate post-transcriptional processes
such as splicing, editing, translation, or localization of the
Prelp or Optc RNA. Interestingly, Prelp and Optc both en-
code extracellular matrix proteins of the family of leucine-
rich repeat (LRR) domain-containing proteins. LRR do-
main containing proteins have been documented to
organize axon guidance, target selection, and synapse for-
mation [76]. Hence, it might be possible that Gm15851
could modulate the establishment of synaptic connections
of POMC neuronal progenitor cells by regulating expres-
sion of Prelp and/or Optc.
Whole transcriptome sequencing of hypothalamic
POMC neurons confirmed the expected expression of
the Opioid proopiomelanocortin release pathways,
known G-protein coupled receptor pathways regulating
feeding and body weight, and the insulin receptor and
leptin receptor signaling pathways. Furthermore, we
confirmed expression of several nicotinic acetylcholine
receptor subunits and acetylcholine metabolizing en-
zymes in POMC neurons [10]. We also detected expres-
sion of specific transport proteins (vGlut2 and vGat)
required for the uptake of glutamate and GABA/glycine
into synaptic vesicles, supporting the notion that POMC
neurons release glutamate and GABA [77, 78].
Several neuroendocrine signaling pathways including
those mediated by the GnRH, TRH, and CRF receptors
were also expressed in POMC neurons. While POMC
neurons regulate reproduction, energy expenditure and
stress responses through activation of hypothalamic
GnRH-producing, TRH-producing, and CRF-producing
neurons, respectively, the reciprocal regulation of POMC
neurons by these hormonal signaling pathways remains
to be explored.
POMC neurons further expressed the netrin, slit, and
semaphorin axon guidance pathways. Netrin, slit, and
semaphorin are secreted or membrane-bound chemotro-
pic proteins that attract or repulse growing axons and
migrating neural progenitor cells by binding, respect-
ively, to the unc, neuropilins, and plexin transmembrane
receptors [79]. These proteins guide migration and neur-
onal outgrowth of hypothalamic oxytocin, antidiuretic
hormone, and GnRH-producing neurons [80–82]. Fur-
thermore, the slit/robo and semaphorin/plexin/neuropi-
lin pathways are expressed during development of the
hypothalamic PVN [83], an important projection site of
POMC neurons. These cell migration and axon guidance
pathways could therefore regulate migration of POMC
neurons and formation of connections to relevant target
sites.
In addition, we found expression of the wnt, integrin,
cadherin, PDGF, EGF, and Notch signaling pathways in
POMC neurons, all of which have been linked to the de-
velopment of hypothalamic neurons. The wnt and integrin
signaling pathways regulate differentiation of hypothal-
amic neuronal progenitor cells [84] and migration of
hypothalamic GnRH producing neurons [85], respectively.
Cadherin signaling regulates neuronal connectivity and
wiring of hypothalamic POMC neurons [86, 87]. The
Notch signaling pathway regulates differentiation of hypo-
thalamic arcuate neural progenitor cells into POMC and
AgRP neurons [88].
Furthermore, hypothalamic POMC neurons expressed
an Alzheimer amyloid secretase and TGF-β signaling
pathway, which included expression of several TGF-β
encoding genes (TGF-β1, TGF-β2, TGF-β3). Both path-
ways have been proposed to be disease-relevant. Exces-
sive production of TGF-β by POMC neurons was found
to promote hypothalamic inflammation and type 2 dia-
betes in obesity and during aging [89]. Expression of an
Alzheimer amyloid secretase pathway suggests participa-
tion of POMC neurons in the pathogenesis of diabetic
comorbidities in Alzheimer’s disease [90].
We attempted to gain insight into probable biological
functions of expressed lncRNAs based on predicted cis-
regulatory interactions with protein-coding genes. This
approach revealed 82 co-expressed lncRNA/coding gene
pairs, 19 of which involved coding genes regulating
neural development and/or function. Most co-expressed
lncRNAs and coding genes overlapped each other. In
around 35 % of co-expressed lncRNA/coding gene pairs,
the lncRNA also overlapped the coding gene promoter.
These observations suggest that some of these lncRNAs
could regulate chromatin state and/or promoter activity
of the coding gene. Furthermore, we found that only one
of the co-expressed lncRNAs was transcribed from an
annotated conserved mouse enhancer. Such eRNAs are
(See figure on previous page.)
Fig. 7 PNE upregulated an antisense RNA, Gm15851, in hypothalamic POMC neurons of adult offspring. a Two-way clustering of RNA-seq expression
data of POMC neurons reveal overlapping gene expression signatures in PNE offspring (N1–N6) and control offspring (C1–C5). The color code represents
the gene expression value in log2CPM. Only genes with average expression levels > 1 CPM across all offspring were considered. b Strand-specific qRT-
PCR confirms overexpression of Gm15851 in POMC neurons of PNE offspring (*, p < 0.05, n = 5–6, two-tailed t test with Welch correction). c Schematic
of genomic localization of Gm15851 within a 28.29 kb segment spanning the chromosomal coordinates 133.9 Mb and 133.92 Mb of chromosome 1.
Gm15851 is a spliced antisense transcript to Prelp and Optc on the forward strand of mouse chromosome 1. Boxes denote exons. Arrowheads denote
gene orientation
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known to mediate gene-specific transcription by facilitat-
ing enhancer-promoter interactions, recruiting transcrip-
tion factors, and blocking enhancer-binding of gene
repressive factors [66, 67]. Several co-expressed coding
genes had annotated functions in nervous system devel-
opment such as Irx3, Msi2 and Ppp1r9a. Irx3 is a
homeobox transcription factor that is expressed in the
prospective neural plate in a subset of neural precursor
cells and possibly regulates specification of neural pro-
genitor cells [91]. Msi1 is a neural RNA-binding protein
that is highly enriched in neural precursor cells and drives
proliferation of neurons and glial cells in the CNS during
embryonic development [92], postnatally and in adults
[93]. Ppp1r9a, also referred to as neurabin, is selectively
expressed in neural tissues, where it induces F-actin cross-
linking activity in the synapse and lamellipodia of the
growth cone to regulate neurite formation [94].
Conclusions
Gestational nicotine exposure may not cause obesity and
type 2 diabetes in first-generation offspring but instead may
moderately enhance central leptin-melanocortinergic regu-
lation of energy and glucose balance via POMC neurons.
Gestational nicotine exposure upregulates Gm15851, a
lncRNA, which might modulate POMC neuronal develop-
ment and/or function. POMC neurons express 82 cis-regu-
latory lncRNA/protein-coding gene interactions, 19 of
which involve coding genes regulating neural development
and/or function, and several previously unidentified meta-
bolic, neuroendocrine, and neurodevelopment pathways.
Additional files
Additional file 1: Table S1. Gene list. Read-pairs were aligned by STAR
to the mouse reference genome. STAR alignments were run through
HTSeq for determination of read-pair counts by genes. Genes are denoted
by their Ensembl gene ID, gene symbol, and gene type (columns A–C).
EdgeR calculated average gene expression values across all offspring
(column D) and fold-changes between nicotine-exposed and control
offspring (FC (N/C), column E). EdgeR (column F), baySeq (column G),
and DESeq (column H) determined differential gene expression. FDR false
discovery rate-adjusted p value, CPM counts per million. (XLSX 2364 kb)
Additional file 2: Table S2. Expressed protein-coding genes in
PANTHER pathways. Expressed protein-coding genes denoted by Ensembl
Gene ID (column A), gene name and symbol (column B), Panther family/
subfamily (column C), Panther protein class (column D), and average
expression in CPM (column E) were assigned to PANTHER defined pathways,
which are referred to by name and accession number. Only genes expressed
at levels > 1 CPM were considered for analysis. CPM counts per million.
(XLSX 172 kb)
Additional file 3: Table S3. Expression ranking of lncRNAs in POMC
neurons. LncRNA genes referred to by Ensembl Gene ID (column A),
gene name (column B), and gene type (column C) were ranked by
average expression across all samples (column D). Only lncRNA genes
expressed at levels > 1 CPM were considered for analysis. CPM counts per
million. (XLSX 98 kb)
Additional file 4: Table S4. Co-expressed lncRNAs and protein-coding
genes in cis. Co-expression of lncRNAs (columns A and B) with their nearest
(adjacent or overlapping) protein-coding gene (column D) was determined
by the Pearson’s correlation coefficient r (column F). An r value >
0.602 or < −0.602 was regarded as significant (p < 0.05, two-tailed t
test, n = 11). Co-expressed lncRNA/protein-coding gene pairs are
ranked by the absolute r value. A positive r value indicates positive
correlation and a negative r value indicates negative correlation (column G).
The distance between lncRNA and protein-coding gene (column H) was
defined as the distance between their nearest borders irrespective of strand
orientation (columns C, E) and was set 0 for overlapping lncRNAs and
protein-coding genes. LncRNAs were positioned upstream, overlapping,
and/or downstream of the coding gene body (column I). A number of
lncRNAs overlapped the coding gene promoter (column J) defined as the
10 kb upstream sequence of a gene. Only lncRNA and coding genes with
average expression levels > 1 CPM (columns K and L) were considered for
analyses. LncRNA expression was in most cases less than that of the coding
gene (column M). Coding genes function in various biological processes
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